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1.1.3 Epidemiology and incidence
Lung cancer has now become one of the world’s leading causes of death,1  with an estimated 
annual incidence of  more than 1.3 million cases and a mortality of more than 1.1 million 
cases worldwide. Epidemiological studies have shown a strong correlation between smoking 
and lung cancer. In fact, Lung cancer mortality can provide a useful measure of a population’s 
exposure to smoking, especially in the population segment aged 35-54, as around 80-90% of 
lung cancer cases are caused by active tobacco consume.2, 3 While lung cancer incidence and 
mortality in men has decreased in recent years (see Figure 1a), mortality in women is still 
increasing with the largest increase in Europe.4, 5 In the EU as a whole, lung cancer mortality 
in men peaked at 55.4 per 100,000 men in 1988 and declined thereafter to 46.7 in 2000.4 In 
women on the other hand, there was an increase in lung cancer mortality from 7.7 per 100,000 
women in 1980 to 11.1 women in 2000. 
Figure 1a. Annual Age-adjusted Cancer Incidence Rates* for Selected Cancers by Sex, United States, 
1975 to 2004. From Jemal, A. et al. CA Cancer J Clin 2008:CA.2007.0010v1-20070010. American 
Cancer Society 2008
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Figure 1b. Mortality rates of lung cancer among men and women in different age groups in 
Norway (1951-1997). With respect to lung cancer-related deaths before the age of 50, women 
surpassed men almost 13 years ago.  Source: Kreftregisteret / Cancer Registry of Norway
Figure 2. Age-standardised (world) mortality rates in Norway 2007 for selected cancers
Source: Kreftregisteret / Cancer Registry of Norway
An alarming feature is the 38% increase of  lung cancer mortality in women aged under 55 
years between 1990 and 2000 (from 2.16 per 100,000 women to 2.99 per 100,000 women), 
reflecting the worrisome spread of cigarette smoking among EU women over the last few 
decades.5 With respect to lung cancer-related deaths before the age of 50 years in Norway, 
women surpassed men almost 13 years ago (Figure 1.b). 
In the the EU member countries there were in 2002 over 227.000 fatal outcomes of patients 
diagnosed with lung cancer.6 In Norway, 1422 men  and 1107 women were diagnosed with 
lung cancer in 2008.7  For lung cancer mortality in both genders in Norway see Figure 2. 
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Other causes of lung cancer are radiation exposure, uranium (with a relative risk RR of 4:1 for 
nonsmokers  and  10:1  for  smokers  vs.  general  population);  asbestos  (RR  with  asbestos 
exposure is 5:1 for nonsmokers,  50-90:1 for smokers vs. general  population),  exposure to 
nickel,  chromate,  coal,  mustard  gas,  arsenic,  beryllium,  iron,  vinyl  chloride  and  radon 
radiation.8-11 
1.1.2 Histopathology
Lung cancers are classified according to non-small-cell carcinoma (NSCLC, 80%) and small-
cell cancer (SCLC, 20%).  NSCLC is histologically a wide classification, when compared to 
SCLC.  The  major  NSCLC  histological subtypes  are  squamous  cell  carcinoma, 
adenocarcinoma with bronchioloalveolar carcinoma and large cell carcinoma (see Figure 3). 
Mixed  histological  subtypes  in  the  same  tumor  can  also  occur.12 Patients  with 
bronchioloalveolar carcinoma have a significant better clinical outcome.
Large cell  carcinoma is  also known as undifferentiated large cell  carcinoma or anaplastic 
carcinoma. Previously, squamous cell carcinomas were most common, but the percentage of 
adenocarcinomas  is  now  increasing  probably  due  to  increased  use  of  filter  cigarettes. 
Adenocarcinoma is also the most common subtype among never smokers. 




Figure 3. Squamous cell carcinoma A, Adenocarcinoma B, Large cell carcinoma C and bronchioloalveolar 
carcinoma D
1.1.3 Staging and TNM
The  majority  of  lung  cancer  patients  are  already  clinically  symptomatic  at  the  time  of 
diagnosis.  The  most  common  symptoms  are  cough,  dyspnea  and  hemoptysis.  Due  to 
diagnosis at a late stage, only (4346/21968; mean 20%) of NSCLC patients in Norway, 1993-
2005, were clinically operable at the time of diagnoses.7 Therapeutical strategies are based on 
both histological and clinical examinations. Clinical examinations include chest x-ray and a 
CT of the chest including the upper abdomen with the adrenal glands. Histological biopsies 
are usually obtained by bronchoscopy for central/hilar tumors or by a CT guided procedure 
for  peripheral  tumors.  According  to  patients  with  enlarged  mediastinal  glands,  a 
mediastinoscopy or an open thoracal surgery is regularly performed to rule out N2-status (see 
Table 1). Recently,  additional  staging tools like positron emission tomography (PET) and 
transesophageal or endobronchial ultrasound have been employed. Clinical TNM (cTNM) are 
based  on  clinical  patient  examinations,  while  pathological  TNM  (pTNM)  is  based  on 
histological examinations. Prognostic significance of cTNM is demonstrated in Table 1. For 
pTNM and clinical stage IIIA see Figure 4 and Appendix 2.
Table 1. Prognostic significance of cTNM stages
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1.1.4 Treatment of NSCLC stage I-IIIA
Complete  surgical resection is the standard treatment for patients in early clinical stage (I-
IIIA) NSCLC. Clinical  trials  have shown improved survival  rates in subsets  of resectable 
NSCLC  patients  administered  preoperative  (neoadjuvant)  and  postoperative  (adjuvant) 
chemotherapy and/or radiotherapy.  Adjuvant chemotherapy is,  however, not recommended 
for stage IA and IB disease.13 For patients with clinical stage II-IIIA, cisplatin-based adjuvant 
chemotherapy is recommended.13-17 Radiotherapy,  in stead for surgery, in stage I-II is only 
indicated for inoperable patients due to age, concurrent diseases or poor clinical performance 
status. For patients with pathological N2 disease stage (metastases to ipsilateral mediastinal 
and/or subcarinal lymphnodes) or incomplete tumor resection postoperative radiotherapy is 
indicated.13-17 For inoperable patients with stage IIIA disease, radical radiotherapy is indicated 
only for those with good prognostic factors (regarding tumor size, performance status, degree 
of weight loss). Otherwise, chemotherapy or palliative radiotherapy is administered.
Figure 4. Adapted from C F Mountain. A new international staging system for lung 
cancer. CHEST 2000
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1.2 MOLECULAR AND GENETIC ABNORMALITIES
1.2.1 Molecular alterations in NSCLC
Several  genetic  abnormalities  and  biomolecular  alterations  have  been  demonstrated  in 
NSCLC.18 Mutations of the tumor suppressor gene TP53 due to loss of one allele at 17p13, a 
locus that harbors the TP53 has been identified in lung cancer.19 There is evidence that such 
alterations in the p53 gene may be induced by tobacco inhalation.20 Other promoter genes 
involved in lung cancer tumorigenesis include tyrosine kinase receptors such as EGFR, as 
well  as  the  myc and  ras oncogenes  family.  While  alteration  of  the  ras oncogene  is  a 
frequently observed event in adenocarcinomas, it is most frequently expressed in smokers.21 
Additionally,  there  are  observations  regarding  increased  DNA-methyltransferase  (DNA-
MTase)  activity  followed by a  hypermethylation  of  normally  unmethylated  gene  regions, 
representing an alternative method for inactivation of tumor suppressor genes, including p16 
and E-cadherin.22 
1.2.2 Therapeutic molecular targets in tumor cells
Preclinical investigations on various types of cancers, including NSCLC, observed a frequent 
overexpression of the tyrosine kinase receptor EGFR. EGFR activation elicits the activation 
of  downstream pathways,  resulting  in  cell  proliferation,  invasion,  metastasis,  and  loss  of 
apoptosis. Interruption of this signaling pathway with a variety of EGFR inhibitors has been 
shown to decrease tumor cell viability, prevent proliferation, or both,  in vitro and  in vivo.23 
Gefitinib and erlotinib are selective EGFR tyrosine kinase inhibitors (TKIs) and were the first 
EGFR-targeted agents to be studied in patients with NSCLC. In phase II trials of gefitinib in 
patients with pretreated metastatic NSCLC, objective tumor response rates of 9–19% were 
seen, and approximately 40% of patients showed improvement of symptoms.24, 25 Meanwhile, 
somatic mutations in exons 19 and 21, corresponding to the tyrosine kinase domain of EGFR 
where  revealed  in  most  patients  responding  to  EGFR  TKI.26,  27 However,  these  specific 
mutations most frequently occur in subsets of lung adenocarcinomas, females, Asians, and/or 
non-smokers.28, 29  
Although most EGFR mutant NSCLCs initially respond to EGFR inhibitors, the vast majority 
of these tumors ultimately become resistant to the drug. It is proposed that activation of other 
Erb family members can play an essential role in development of this drug resistance. This 
has led to a search for combinations of drugs, simultaneously inhibiting different tyrosine 
kinase receptors. Clinical NSCLC trials have also reported improved survival in patients with 
12
HER2 gene amplification after blockade of the HER2 receptor.30 Investigations concerning 
HER3 activation are also ongoing. Recently, the MET proto-oncogene (a HER3 activator) has 
become  an  interesting  inhibition  target  in  NSCLC.31 Angiogenesis  i.e.  formation  of  new 
vasculature  for  tumor  blood  supply  has  also  emerged  as  an  interesting  target  in  cancer 
therapy, also in lung cancer. A phase III trial in NSCLC patients using bevacizumab (inhibitor 
of  VEGF/VEGFR2)  presented  an  improved  response  rate,  progression-free  survival  and 
overall survival. Though the median survival benefit was modest, from 10.3 to 12.3 months, 
the drug has been approved by both EMEA and FDA.32 However, a similar later study did not 
show any difference regarding overall survival.33
Research within molecular cancer biology found the protein kinase B (Akt) signaling pathway 
to  be  central  in  cellular  proliferation  and  survival.  Being  disrupted  in  many  human 
malignancies with wide-ranging biological consequences, the PI3K/Akt signaling pathway is 
considered  an  essential  target  of  various  antitumor  drugs,  including  UCN-01  (7-
hydroxystaurosporine) and geldanamycin analogues.34
1.2.3 Potential of new molecular targets in cancer
Molecular  markers  of  neoplastic  tissue  are  now  gaining  ground  as  prognosticators  and 
possible therapeutical targets. Identification of molecular markers involved in critical cancer 
pathways may present interesting approaches for therapeutical  regimes.  Thus it is of huge 
interest to investigate the prognostic and/or the predictive significance of different biological 
markers in malignancies. Having mentioned this, we should not underestimate the prognostic 
significant  power  of  various  clinical  and  histological  variables  (such  as  tumor  size, 
differentiation, tumor stage and performance status). Since new potential molecular targets 
are discovered almost on a daily basis, a serious concern may be the necessary selection of 
which biomarkers to investigate. Immunohistochemistry has played a critical role in assessing 
new biomarkers, but new, more comprehensive and effective methods seem to be needed in 
the near future to improve our understanding of tumor biology and progression.35
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1.3 Tumor differentiation and proliferation
Cancer  cells  undergo  complex  genetic  aberrations  through  the  different  stages  of 
carcinogenesis. Genomic instability or selection leads to aberrations that can be grouped into 
six essential pathways as proposed by Hanahan and Weinberg36 in 2000: Acquisition of (1) 
self-sufficient  or  autonomous  growth  signals;  (2)  insensitivity  to  anti-growth  signals;  (3) 
resistance  to  signals  of  apoptosis;  (4)  unlimited  replicative  potential;  (5)  sustained 
angiogenesis;  and  (6)  invasion  of  tissue  and  metastasis.  Each  of  these  mechanisms  is 
regulated of several pathways which further interact with a complex roadmap of subpathways. 
Despite this complexity,  there is mounting evidence that certain molecular aberrations are 
more likely to influence the clinical  behavior of a malignant  tumor,  including the risk of 
metastasis.37-40 Investigating such aberrations in prognostic markers can not only potentially 
influence and predict the clinical outcome of a cancer patient, but also open possibilities for 
new interesting therapeutical targets.41 There are several methods for determining alterations 
in  molecular  prognostic  markers:  Changes  in  gene  copy  number  by  means  of 
silver/fluorescence  in situ hybridization; messenger RNA (mRNA) expression, and protein 
expression levels using immunohistochemistry (IHC). 
1.3.1 Tumor proliferation
A  balance  between  stimulators  and  inhibitors  of  cell  proliferation  maintains  growth 
homeostasis in normal cells. Resistance to growth-inhibitory factors is an essential step in 
carcinogenesis.  The  cell  population  of  tumor  tissues  is  determined  by  the  rates  of  cell 
proliferation, differentiation, and death by apoptosis.42 The proliferative behavior of a tumor is 
important  for  establishing  therapeutic  regimes  and  for  predicting  prognosis.  Various 
techniques have been developed to quantify tumor proliferation rates. Mitotic count, using 
light microscope, are widely used as a simple measure of cellular proliferation and are often 
incorporated into tumor grading systems.43 Other methods have been developed, such as the 
detection of cells undergoing DNA synthesis,44 flow cytometry to estimate the percentage of 
cells in S phase of the cell cycle or the detection of antigens associated with proliferation. 
Evaluating the mitotic index can be performed on paraffin-embedded specimens using light 
microscopy with  simple  staining  methods.  However,  there  may be  inter-  and  even intra-
observer  variability  in  counting.  Some  morphologic  changes  in  cells  (e.g.  apoptosis,  or 
nuclear  pyknosis)  can  also  be  miscounted  as  mitosis.  On  the  other  hand,  using  specific 
antigens can be both expensive and time consuming but examinations can be performed on a 
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small  amount  of  tissue.  A  known  immunohistochemical  marker  is  the  nuclear  antigen 
Ki67/MIB-1 which is widely used on routine basis for diagnostic purposes. Different marker 
expressions  which were investigated  in  this  study are  correlated  both to  proliferation  and 
differentiation of tissue.
1.3.2 Tumor differentiation and epithelial-mesenchymal transition
Differentiation  refers  to  the  extent to  which  neoplastic  cells  both  morphologically  and 
functionally resemble normal mature cells of the tissue of origin in a given organ. Malignant 
neoplasms  range from well  differentiated  to  undifferentiated.  Poorly differentiated  tumors 
consist of primitive-appearing,  unspecialized cells.  This lack of differentiation (also called 
anaplasia)  is  marked by a  number  of morphologic  changes,  such as variation  in  size and 
shape,  i.e.  pleomorphism,  dark  stained  nuclei  due  to  abundance  of  DNA  (called 
hyperchromasia),  loss of orientation (loss of polarity,  i.e.  poorly differentiated tumor cells 
grow in  disorganized  sheets).  There  is  mounting  evidence  suggesting  that  this  change  in 
tumor  tissue  architecture  takes  place  through a  peculiar  phenotype  modulation  known as 
epithelial-mesenchymal transition (EMT). EMT involves dedifferentiation of epithelial cells 
to  fibroblastoid,  migratory  and  more  invasive  cells,  showing  a  profoundly  altered 
mesenchymal gene expression profile.45, 46 The essential features of EMT are the disruption of 
intercellular contacts and the enhancement of cell motility leading to metastases. Although the 
molecular bases of EMT have not been completely elucidated, several cellular transduction 
pathways  and a number  of signaling molecules  potentially  involved have been identified. 
EMT  also  occurs  during  embryonic  development  as  epithelial  cells  lose  their  polarized 
phenotype, a process which is regulated by an interplay of different signaling pathways.47-50 
An example of these processes includes tubulogenesis and branching in the mammary gland, 
mesoderm formation  during gastrulation,  and palate  fusion and emigration  of neural-crest 
cells from the neural tube.
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1.3.3 Factors and receptors of tumor proliferation and differentiation
1.3.3.1 Proteins involved in inflammatory processes and tumorigenesis
Epidemiological  studies  have  revealed  inflammation  as  a  critical  component  of  tumor 
progression. Many cancers arise from sites of infection and chronic irritation. There is also 
evidence that usage of non-steroidal anti-inflammatory agents is associated with protection 
against certain malignancies. Different cellular components are involved in the inflammatory 
process  at  the invading  edge of cancer,51-53 including  white  blood cells,  macrophages  and 
fibrocytes.  Several  proteins54 and  proliferation  markers55,  56 are  found  in  areas  with 
inflammation. The transcription factor Nuclear factor-kappa binding (NF-κB ) is activated in 
a  range  of  inflammatory  processes  and  human  cancers  and  is  thought  to  promote 
tumorigenesis.55, 57 A link between aberrant NF-κB  activity and cancer was initially implied by 
the identification of v-Rel, a viral homolog of c-Rel, as the transforming oncogene of an avian 
retrovirus  that  causes  aggressive  tumors  in  chickens.58 Moreover  NF-κB  is  activated  by 
oncogenic  viruses,  such  as  human  T  cell  leukemia  virus  I  or  Epstein-Barr  virus.59,  60 
Constitutive  nuclear  NF-κB  activity  has  emerged  as  a  hallmark  of  many  other  human 
leukemias, lymphomas, and solid tumors.57, 61 
NF-κB  is  a  group  of  proteins  that  control  inflammation,  cell  survival,  transformation, 
proliferation,  angiogenesis  and apoptosis.62 It  is  normally retained  in  the cytoplasm in an 
inactive state through interaction with inhibitor kB (IkB) (Figure 5).57 Degradation of the IkB 
proteins results in the liberation of NF-κB , allowing nuclear translocation and the activation 
of  target  genes,  including  Snail  and  Bcl-2.63 Five  mammalian  NF-κB proteins  have  been 
identified: p65 (RelA), NF-κB 1 (p50 and its precursor p105), NF-κB 2 (p52 and its precursor 
p100), c-rel and RelB. These bind to DNA as homo- or heterodimers.64 Unlike RelA, RelB, 
and c-Rel, the p50 and p52 NF-κB  subunits do not contain transactivation domains in their C 
terminal  domain.  Nevertheless,  the  p50  and  p52  NF-κB   members  play  critical  roles  in 
modulating the specificity of NF-κB  function. Although homodimers of p50 and p52 have 
been described as repressors of kB site transcription, both p50 and p52 participate in target 
gene transactivation by forming heterodimers with RelA, RelB, or c-Rel.65 In addition, p50 
and p52 homodimers also bind to the nuclear protein Bcl-3, and such complexes can function 
as transcriptional activators.66-68
16
Figure 5. Mechanisms of NF-kB activation. Adapted from Glimore TD (2006). “introduction 
to NF-kB: players, pathways, perspectives”. Oncogene 25 (51): 6680-4.
1.3.3.2 Regulators of cell polarity
Polarization of epithelial  cells resting on the basal membrane is a feature of differentiated 
tissue.  On  the  other  hand,  loss  of  polarization  accompanied  by  other  morphologic  and 
functional changes such as fibroblastoid (mesenchymal) morphology and enhanced motility is 
a feature of aggressive tumors.  While  mechanisms of cell  polarity are quite complex,  the 
partitioning-defective  protein-6  and  atypical  protein  kinase  protein  complexes  C  (Par6- 
aPKC) localized  to  the  apical  membrane  domain  have  emerged  as  central  players  in  the 
regulation of cell polarity and the asymmetric division of cells.69-72 
The intermediate filament protein vimentin is  a structural protein from cells of mesenchymal 
origin73 and was initially isolated from a mouse fibroblast culture.74, 75 Its expression is higher 
in migratory epithelial cells and may contribute to the migratory and invasive phenotype of 
metastatic cells.76 Significant correlations between high vimentin tumor cell expression and 
poor prognosis have previously been reported in various malignancies.77, 78 
Fascin is an actin-bundling and crosslinking protein that binds to preformed filaments and 
regulates their  organization and stability.  It is presumed to regulate cortical cell membrane 
protrusions.79 Its overexpression is induced by Epstein Bar virus infection in a subset of B-
lymphocytes80 and is proposed to increase the motility of epithelial cells.81, 82
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1.3.3.3 Growth factors
Transforming growth factor-beta  (TGF-ß)  is  a  chemokine with multifunctional  regulatory 
aspects  of  cellular  functions  including  cellular  proliferation,  differentiation,45 migration, 
apoptosis, adhesion, angiogenesis, immune surveillance, and survival.83,  84 Although TGF-ß 
regulates proliferation of normal tissue and suppresses early tumorigenesis; it demonstrates 
however, a paradoxical action as a tumor promoter in later stages of tumor progression.85 It 
can  also  facilitate  malignant  transformation  through  manipulating  a  more  hospitable 
environment for tumor invasion and the development of metastases. Overexpression of TGF-ß 
is proposed to enhance tumorigenesis not only by stimulating angiogenesis and suppressing 
the immune system, but also by acting directly on neoplastic cells in some malignancies.86-90 
Elevated  expression  of  TGF-ß  has  been  correlated  to  poor  clinical  outcome  in  different 
malignancies,91 hence various components of the TGF-ß signaling pathway offer potentially 
attractive therapeutic targets for cancer treatment.92
1.3.3.4 Regulators of cell adhesions
E-cadherin is a cell adhesion molecule expressed in epithelial cells93, 94 and plays an essential 
role  in  epithelial  tissue  formation.  In  the  cytoplasm,  E-cadherin  is  anchored  to  the  actin 
cytoskeleton via the E-cadherin–binding h-catenin and a-catenin,95 which is crucial for the 
dynamic regulation of cellular differentiation, proliferation and migration.95 There is evidence 
that instability of the E-cadherin complex in malignant cells contribute to a functional loss of 
cell-cell adhesion.96, 97 Interaction of tumor stromal cells with epithelial cells has been shown 
to result in a hyperphosphorylation of E-cadherin complexes,  inducing the disassembly of 
their adhesion complexes and contribution to tumor progression.98
1.3.3.5 Growth factor tyrosine kinase receptors
The  human  epidermal  growth  factor  receptor  (Erb)  family  consists  of  four membranous 
tyrosine kinases (EGFR, HER2, HER3 and HER4), which differ in ligand specificity.99, 100 The 
genes  for  the  HER family of  receptors  are  designated  erbB1 (EGFR), erbB2, erbB3,  and 
erbB4.101 The  amino  acid  sequences  of  the  HER receptors  are  highly  homologous  to  the 
epidermal  growth  factor  receptor  (EGFR).  The  binding  to  ligands  elicits  their  homo-  or 
heterodimerization  and  kinase  domain  activation  initiating  cascades  of  cytoplasmic  and 
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nuclear mitogenic pathways including the RAS-MAP and PI3K-Akt pathways, which lead to 
gene activation and cell proliferation (Figure 6).102 HER1 (EGFR) binds to different ligands 
(e.g., TGF-α and amphiregulin).103 While there are no known ligands for HER2,104 evidence 
indicates that isomorphs of the new differentiation factor (NDF or neuregulins) function as 
ligands for both HER3 and HER4.103 It has been proposed that HER3 lacks intrinsic kinase 
activity  as  a  single  protein  but  can  transduce  signals  following  heterodimerization.105,  106 
Amplification  of  HER2  gene  and  overexpression  of  its  encoded  protein  appeared  to 
negatively  influence  survival  in  about  30% of  breast  cancer  patients.107 Whereas  specific 
inhibition of HER2 gene amplified breast cancers resulted in an improved patient survival.108
Figure 6. Simplified schematic illustration of homo- and heterodimers of erb family 
members transducing signals to different oncogenes. *Presumed nuclear translocation of 
membranous HER3.
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1.3.3.6 Signaling Pathway linking EGFR activation
Ligands  binding  to  human  EGFR  elicit  kinase  domain  activation  initiating  cascades  of 
cytoplasmic pathways. A cytoplasmic pathway of central role in cell activity is the PI3K-Akt 
pathway.102 The atypical protein kinase B (PKB/Akt) family consists of three serine/threonine 
protein  kinase  isoforms  Akt1/PKBα,  Akt2/PKBß and  Akt3/PKBγ,  which  function  as  key 
regulators  for  cell  growth,  survival  and  proliferation.  Other  processes  regulated  by  Akt 
isoforms  include  cell  size,  cell  response to  nutrient  availability,  intermediary  metabolism, 
angiogenesis  and tissue invasion.109 Deregulations of these kinases have been described in 
human malignancies.110 In order to be activated, Akt1 is recruited to the cellular membrane by 
binding  of  its  amino  terminal  pleckstrin  homology  (PH)  domain  to  membrane-bound 
phosphatidylinositol 3,4,5 triphosphate (PIP3),111 which is followed by the phosphorylation of 
two key amino acids: i) threonine 308 (Thr308) in the P-loop of the protein kinase domain 
and ii) serine 473 (Ser473) in the carboxy-tail region.112
This pathway is regulated by other kinases; PI3K activates Akt by catalyzing the production 
of its dependent kinases phosphoinositide-dependent kinase and integrin-linked kinase.113-115 
The tumor suppressor phosphatase and tensin homologue deleted on chromosome ten (PTEN) 
is a phospholipid phosphatase which negatively regulates phosphatidylinositol triphosphate 
levels thus antagonizing PI3K.116 Frequent inactivation and loss of function mutations have 
been described for PTEN in different malignancies.117, 118
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1.4 Epithelial mesenchymal transition and relation to tumor stroma
Stromal–epithelial interactions are considered critical for regulating tissue development and 
for  the  maintenance  of  tissue homoeostasis.119 Consequently,  it  seems  essential  to  study 
molecular marker alterations in stromal cells surrounding neoplasia to better understand the 
mechanisms  of  tumor  growth  and  proliferation.  Stromal  cells  surrounding  the  advancing 
tumor edge (also called tumor stroma) consists of 1) non-malignant cells related to the tumor; 
activated  fibroblasts,  specialized  mesenchymal  cell  types  distinctive  to  each  tissue 
environment, innate and adaptive immune cells, and the vasculature with endothelial cells and 
pericytes, as well as 2) the extracellular matrix (ECM).120 ECM consists of structural proteins 
(collagen, elastin), specialized proteins (fibrilin, fibronectin, elastin) and proteoglycans. It is 
now  becoming  clear  that  the  tumor  microenvironment,  which  is  largely  orchestrated  by 
inflammatory cells,  is a major participant in the neoplastic process, fostering proliferation, 
survival and migration. Thus a rather paradoxical role of stromal cells is to be appreciated. 
Stromal cells appear, in some instances, to support growth and motility of tumor cells,121 and 
in other instances to be a part of the microenvironment preventing tumor cell invasion, in 
concert with the assumed function of the immune system. This complex interplay between 
tumor  epithelial  cells  and  stromal  cells  can  be  further  complicated  by  morphological 
observations  describing  tumor  epithelial  cells  to  gain  a  mesenchymal  or  a  stromal  cell 
appearance.122 Since  1989,  this  phenomenon  of  morphological  alterations  (later  called 
epithelial  mesenchymal  transition;  EMT)  has  been  linked  to  cancer  development,  as  rat 
bladder carcinoma cells were seen to have a changed morphology. These cells were missing 
desmosome  junctions,  and  had  a  rearranged  cytoskeleton.123,  124 All  the  above  mentioned 
prognostic markers (chapter 1.3.3) are described to play a role, either directly or indirectly, in 
the differentiation of tumor tissue and can, to a varying degree, be linked to the phenomenon 
of EMT in tumor tissue. However, even though EMT can be described as a set of changes 
where  malignant  epithelial  cells  lose  their  polarity,  and  acquire  a  spindle-shaped,  highly 
motile fibroblastoid phenotype following loss or redistribution of tight- and adherens-junction 
proteins  and  alteration  in  gene-expression,  there  is  still  no  consensus  about  a  clear-cut 
definition  of  this  morphological  and functional  phenomenon  or  an established  number  of 
altered  molecular  markers  in  these cells.  As previously mentioned EMT also occurs as a 
physiological  process during embryonic  development,  and is  regulated  by an increasingly 
complex pattern of signaling pathways.47-50
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Figure 7. Tissue microarray method with donor block and recipient. Slices can be cut and 
used for various staining methods. Adpated  from W. Chen, D.J Foran/ Analytica Chemica 
Acta 564 (2006) 74-81
1.5 Tissue microarray
Tissue microarray (TMA) is a powerful technology tool designed to investigate the expression 
of  proteins  or  genes  efficiently  and  economically  across  large  sets  of  tissue  specimens, 
assembled on a single microscope slide.125 This method implies the extraction of small tissue 
cylinders from a donor tissue block (usually formalin-fixed paraffin-embedded tissue) to be 
embedded in a “recipient” paraffin block (see Figure 7).
About 200 consecutive sections of 4–8 micrometer  thickness can be cut from each tissue 
microarray block. These sections can then be stained with different markers to establish a 
large-scale protein or gene expression profile of cancers. This method allows the assessment 
of; DNA using fluorescent/silver  in situ hybridization (FISH/SISH), RNA using mRNA  in  
situ hybridization (RNA-ISH), or protein expression using immunohistochemistry (IHC). The 
terminology should not lead to confusion with the DNA microarrays, in which each tiny spot 
on the grid represents a unique cloned complementary DNA (cDNA) or oligonucleotide. A 
major advantage using TMA is saving time and money assessing protein expression, since a 
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large number of small core biopsies can be assessed on just one slide representing numerous 
tumors,  rather than staining individual slides for each tumor.  And only few microliters of 
antibody  are  enough  to  stain  multiple  tumors  on  one  slide.  Furthermore,  staining  and 
assessing several tumors on one slide implies that the different specimens are treated in an 
identical  manner.  This  is  critical,  when  comparing  the  molecular  expression  of  different 
tumors.
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2. Aims of thesis
A major goal of this study was to elucidate the prognostic roles of tumor proliferation and 
differentiation  markers  in  NSCLC,  and  to  explore  their  prevalence  in  both  stromal  and 
epithelial malignant cells. 
More specifically the aims were:
● To assess the prevalence and prognostic significance of NF-κB p105, vimentin, E-cadherin, 
atypical PKC, Par6, fascin and transforming growth factor-ß (TGF-ß) in tumor stromal and 
tumor epithelial cells of resected NSCLC tumors
● To determine the prevalence and prognostic significance of all three known Akt isoforms 
(Phosphorylated Akt1, non-phosphorylated Akt2 and total Akt3) as well as PTEN and PI3K, 
upstream members of the PI3K/Akt signaling pathway
●  To examine the prevalence and prognostic role of Erb family members (EGFR, HER2, 
HER3 and HER4) in NSCLC as single proteins and as pairs
○ Compare the expression of HER2 as detected by IHC with its gene amplification by means 
of SISH stratified for clinical variables
○ Investigate the correlation between nuclear and cytoplasmic expression of HER3 and their 
prognostic significance
○ Determine the correlation between polysomy of chromosome 17, the chromosome on which 
the HER2 gene is located, and disease-specific survival in NSCLC patients
24
3. Patients and methods
3.1 Patients and clinical samples
The  same  study  population  was  used  in  all  three  papers.  Primary  tumor  tissues  from 
anonymized  patients  diagnosed with NSCLC pathologic  stage I  to  IIIA at  the University 
Hospital  of North Norway (UNN) and the Nordland Central  Hospital  (NLSH) from 1990 
through 2004 were used in this retrospective study. As shown in Figure 8, 371 patients were 
registered from both hospital databases. Of these, 36 patients were non-eligible for the study 
due to: (i) Radiotherapy or chemotherapy prior to surgery (n = 10); (ii) Other malignancy 
within five years prior to NSCLC diagnosis (n = 13); (iii) Inadequate paraffin-embedded fixed 
tissue  blocks  (n  =  13).  Thus  335  patients  with  complete  medical  records  and  adequate 
paraffin-embedded  tissue  blocks  were  eligible.  This  report  includes  follow-up  data  as  of 
September  30,  2005.  The  median  follow-up  was  96  (range  10-179)  months.  Complete 
demographic and clinical data for all patients were collected retrospectively by an oncologist 
(T. Dønnem). The last patient update was performed in November 30, 2008. Formalin-fixed 
and paraffin-embedded  NSCLC tumor  specimens  were obtained  from the  archives  of  the 
Departments  of Pathology at  UNN and NLSH. The tumors  were staged according  to  the 
International Union Against Cancer’s TNM classification126 and histologically subtyped and 
graded  according  to  the  World  Health  Organization  guidelines.12 The  National  Data 
Inspection Board and The Regional Committee for Research Ethics approved the study.
Figure 8. 335 patients with complete medical records were included
25
3.2.1 Tissue microarray construction
All lung cancer cases were histologically reviewed by two pathologists (S. Al-Saad and K. 
Al-Shibli) and the most representative areas of tumor cells (neoplastic epithelial cells) and 
tumor stroma were carefully selected and marked on the hematoxylin and eosin (H/E) slide 
and  sampled  for  the  TMA  blocks.  The  TMAs  were  assembled  using  a  tissue-arraying 
instrument  (Beecher  Instruments,  Silver  Springs,  MD,  USA),  consisting  of  thin-walled 
stainless steel biopsy needles and stylets used to extract tissue cylinders from the donor block, 
transfer  the  needle  content  and  empty  it  into  the  recipient  block.  Tissue  cylinders  were 
retrieved from selected regions of the donor block. The recipient block was held in an X-Y 
position guide that was manually adjusted by micrometers, and the instrument was used to 
create holes in the recipient paraffin block. Thereafter, cores from the donor blocks where 
transferred to the pre-made holes in the recipient block by a solid stylet,  closely fit in the 
needle. The tissue cores were transferred to the recipient block at defined array coordinates. 
We used a 0.6 mm diameter needle, and the study specimens were routinely sampled with two 
replicate  core samples  (different  areas)  of  neoplastic  tissue and two of tumor  stroma.  To 
include  all  core  samples  including  controls,  eight  tissue  array  blocks  were  constructed. 
Multiple 4 μm sections were cut with a Micron microtome (HM355S) and stained by specific 
antibodies for immunohistochemistry (IHC) analyses. For paper III, sections were also stained 
by specific antibodies for silver in situ hybridization (SISH) analyses.
3.2.2 Advantages and disadvantages with TMA technology
As previously mentioned (see 1.5) TMA technology is both an efficient (time saving) and 
economical  (antibody  saving) method.  Further  it  allows  a  more  objective  comparison  of 
antibody expression in a large number of tissues (up to 300) obtained from different tumors 
on the same slide.127 A common concern is whether the small  core samples used in TMA 
analysis  give meaningful information about the large tumor specimens. Instead of 0.6 mm 
cores,  some  investigators  have  used  larger  cores  (2-4  mm  or  more)  to  increase 
representativity.  Others  suggest  that  punching multiple  small  cores  from different  regions 
captures the heterogeneity of the tumors better.125 Hence, we chose to use duplicate cores of 
both tumor cells and stromal cells, and to sample from as representative sites as possible after 
reviewing  all  the  original  sections  of  the  tumor  and  taking  tumor  heterogeneity  in 
consideration. In addition, the total surface areas of all cores were counted (rather than using 
1-2 high power fields). Up to 95% correlation has been demonstrated when comparing tumor 
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cell assessment in duplicate 0.6 mm cores versus the whole slide.125 However, representativity 
of  using  TMA  for  other  variables  (including  lymphocytes)  may  be  slightly  lower  when 
compared to evaluations of bigger sections, but it is still highly representative.128 Still, there 
are no published data on the TMA’s representativity with respect to the assessment of stromal 
cells.  This  has  been  explained  further  in  the  methods.  However,  in  complex  tissues  that 
require simultaneous investigation of various regions of an organ, a larger core diameter may 
be preferable. This was concluded in research performed on liver tissue, where at least one 
acinus was necessary to be included in each core, and 2 mm core diameter was the most 
adequate.129 
3.3 Immunohistochemistry (IHC)
IHC as a method for detecting and visualizing antigens in paraffin-embedded tissue is both 
highly  sensitive  and  specific130 and  is  considered  the  most  practical  method  of  assessing 
protein expression changes in diagnostic histopathology. Using IHC does not only enable a 
semiquantitative  assessment  of  protein  abundance,  but  can  also  localize  the  protein 
expression. It may also detect functionally important post-translational protein modifications, 
such as phosphorylation. These considerations have led to the extensive use of IHC in studies 
on  prognostic  and  predictive  markers  for  different  tumors.41 Yet,  the  specificity  of  an 
immunohistochemical test would never exceed the specificity of the antibody provided by the 
manufacturer. Nevertheless, an additional possible source of error can still be the biological 
variation of protein expression in different areas of tumor tissue. Nonetheless, this source of 
bias can be reduced by increasing the number of examined tissue as in this study. IHC as a 
method is briefly based on applying a specific primary antibody which binds to the antigen of 
interest. This reaction is usually amplified by a biotinylated  secondary antibody, an enzyme 
complex and a chromogenic substrate for visualizing the aimed antigen. 
3.3.1 IHC procedure
Paper I: For staining with fascin and NF-κB  p105, sections were deparaffinised with xylene 
and rehydrated with ethanol. Antigen retrieval was performed by placing the specimen in 0.01 
mol citrate buffer at pH 6.0 and exposed to two repeated microwave heatings of 10 min at 
450W. Primary antibodies for fascin and NF-κB  p105 were incubated for 30 min at room 
temperature. For staining with vimentin, E-cadherin, atypical PKC, Par6, and transforming 
growth  factor-b  (TGF-ß)  the  slides  were  transferred  to  the  Ventana  Benchmark,  XT 
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automated slide stainer (Ventana Medical System, Illkirch, France). The DAKO En- Vision+ 
System-HRP (DAB) kit was used to visualise the antigens for all stains. This yielded a brown 
reaction product at the site of the target antigen. Tissue sections were incubated with primary 
antibodies  recognising  vimentin,  E-cadherin,  Par6,  aPKC and  TGF-ß.  Primary  antibodies 
were incubated at 37˚C (vimentin 24 min, E-cadherin 32 min, aPKC 28 min, Par6 52 min and 
TGF-ß 28 min). 
Paper II: The antibodies  used in  the study were as follows:  Phospho-Akt (Ser473)  (1:5; 
rabbit monoclonal, clone 736E11; #3787; Cell Signaling Technology, Danvers, USA), which 
detects  Akt1  only  when  phosphorylated  at  serine  473,  and  Akt2  and  Akt3  only  when 
phosphorylated at  equivalent  sites;  Phospho-Akt (Thr308) (1:50; rabbit  monoclonal,  clone 
244F9; #4056; Cell Signaling Technology),  which recognizes all three Akt isoforms when 
phosphorylated at threonine 308; Akt2 (1:18; rabbit monoclonal,  clone 54G8; #4057; Cell 
Signaling Technology), which preferentially binds to non-phosphorylated endogenous levels 
of  Akt2  and  does  not  cross-react  with  recombinant  Akt1  or  Akt3;  Akt3  (1:8;  rabbit 
polyclonal,  #4059;  Cell  Signaling  Technology),  which  detects  endogenous  levels  of  total 
Akt3,  but  does not recognize  the truncated  form of rat  Akt3 nor  does  it  cross-react  with 
recombinant  Akt1  or  Akt2;  PTEN  (1:10;  rabbit  monoclonal;  #9559;  Cell  Signaling 
Technology), which detects endogenous levels of total PTEN protein; PI3-kinase (1:25; rabbit 
polyclonal;  #4254;  Cell  Signaling  Technology),  which  detects  endogenous  levels  of  total 
PI3K.  Sections  were  deparaffinized  with  xylene  and  rehydrated  with  ethanol.  Antigen 
retrieval was performed by placing the specimen in 0.1 mol/l citrate buffer at pH 6.0 and 
exposing  it  to  two  repeated  microwave  heating  of  10  minutes  at  450  W.  The  DAKO 
EnVision+ System-HRP (DAB) kit  (Glostrup,  Denmark)  was  used as endogen peroxidise 
blocking. Primary antibodies were incubated overnight at 4˚C (except PI3K, for 32 minutes at 
room temperature). 
Paper III: The antibodies used in the study were as follows: Phospho-EGF Receptor/EGFR 
(1:250; rabbit  monoclonal,  clone 53A5; #4407; Cell Signaling Technology,  Danvers, MA, 
USA); HER2/neu (pre diluted by the manufacturer; rabbit monoclonal, clone 4B5; #790-100; 
Ventana  Medical  Systems,  Illkirch,  France);  Nuclear  non-phosphorylated  HER3  receptor 
(HER3n)  (1:250;  mouse  monoclonal,  clone  RTJ2;  #NB100-2691;  Novus  Biologicals, 
Littleton,  CO,  USA);  Phospho-HER3  (p-HER3)  (1:250;  rabbit  monoclonal,  clone  21D3; 
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#4791;  Cell  Signaling  Technology,  Danvers,  MA,  USA);  HER4 (1:50;  rabbit  polyclonal, 
#RB-9045-R7; Thermo Fisher Scientific Anatomical Pathology, Fremont, CA, USA). 
All the used antibodies in the three above mentioned studies had been subjected to in-house 
validation by the manufacturer for IHC analysis on paraffin-embedded material. The DAKO 
EnVision+ System-HRP (DAB) kit  was used to visualize the antigens  for all  stains.  This 
yielded  a  brown  reaction  product  at  the  site  of  the  target  antigen.  As  negative  staining 
controls, primary antibodies were replaced with the primary antibody diluent. All slides were 
counterstained  with  haematoxylin  to  visualize  the  nuclei.  For  each  antibody,  including 
negative controls, all TMA stainings were performed in a single experiment. The antibodies 
used in the three studies are shown in Table 2.
Table 2. The investigated antibodies using immunohistochemistry
Antigen Antibody Catalog # Source Dilution
NF-kB p105 Rabbit monoclonal 4808S Cell signaling 1:50
Vimentin Mouse monoclonal 790-2917 Ventana a
E-cadherin Mouse monoclonal 760-2830 Cell Marque a
Par6 Rabbit polyclonal Sc-25525 Santa Cruz 1:10
aPKC Rabbit polyclonal Sc-216 Santa Cruz 1:100
Fascin Mouse monoclonal MAB3582 Chemicon 1:25
TGF-ß Rabbit polyclonal Sc-146 Santa Cruz 1:50
p-Akt Ser473 Rabbit monoclonal 3787 Cell Signaling 1:5
p-Akt Thr308 Rabbit monoclonal 4056 Cell Signaling 1:50
Akt2 Rabbit monoclonal 4057 Cell Signaling 1:18
Akt3 Rabbit polyclonal 4059 Cell Signaling 1:8
PTEN Rabbit monoclonal 9559 Cell Signaling 1:10
PI3K Rabbit polyclonal 4254 Cell Signaling 1:25
p-EGFR Rabbit monoclonal 4407 Cell Signaling 1:250
HER2/neu Rabbit monoclonal 790-100 Ventana a
Nuclear HER3 Mouse monoclonal NB-100-2691 Novus Bio. 1:250
p-HER3 Rabbit monoclonal 4791 Cell Signaling 1:250
HER4 Rabbit polyclonal RB-9045-R7 Thermo Fisher 1:50
a=Prediluted by the manufacturer
29
3.4 Silver in situ hybridization (SISH)
In recent years, more focus has been attributed to specific genetic changes in the DNA of 
neoplastic cells. Therefore, methods visualizing nucleic acids for investigating gene status 
were highly needed. In 1969, a method called fluorescence in situ hybridization (FISH) was 
introduced by Gall and Pardue, where they used radiolabeled probes for visualizing specific 
nucleic  acids.131 As recent  as 1980, Bauman and Wiegant  et  al,  used FISH to visualize 
specific DNA sequences in the insect Crithidia luciliae.132 This method has been developed 
over time and has now become a specific and reliable method for investigating different 
gene status.133 However, this technique is not easy to perform or to interpret and it requires 
expensive instruments such as highly sensitive immunofluorescence microscopy, making it 
a particular challenge for many laboratories. Recently, a new method, called silver  in situ 
hybridization (SISH), has been introduced. This new method offers the accuracy of FISH 
with  the  use  of  silver  staining,  instead  of  fluorescent  signals,  thus  allowing  the  use  of 
ordinary light microscopy which is available for all histopathologists. The method is also 
fully automated, which ensures consistency with respect to methodology and results.134 
In our study, automated SISH was performed on a Ventana Benchmark XT, according to the 
manufacturer’s  protocols for the INFORMHER2 DNA and chromosome 17 probes. The 
applied  antibodies  (see  Table  3)  have  been  subjected  to  in-house  validation  by  the 
manufacturer for detection of the HER2 gene (HER2sish) and chromosome 17 (chrom17) in 
paraffin-embedded material. The antibodies used for SISH staining were as follows: HER2 
DNA probe (anti-rabbit,  ref:  780-4332;  Ventana Medical  Systems,  Illkirch,  France)  and 
chromosome  17  probe  (anti-rabbit,  ref:  780-4331;  Ventana  Medical  Systems,  Illkirch, 
France). Sections were deparaffinized with xylene and rehydrated with ethanol. The probes 
were labelled with dinitrophenol (DNP) and visualized using the rabbit anti-DNP primary 
antibody and the Ultraview SISH Detection Kit. Both the HER2 DNA and the chromosome 
17 probes were denatured at 95°C for 12 min, and hybridization was performed at 52°C for 
8h.  The  final  reaction  product  was  black  metallic  silver,  which  was  produced  by  the 
sequential  addition  of  silver  acetate,  hydroquinone  and  hydrogen  peroxide  to  the 
peroxidase-conjugated goat anti-rabbit antibody from the detection kit. The metallic silver 
was deposited in the nuclei, and a single copy of the HER2 gene or chromosome 17 was 
seen as  a  discrete  black  dot.  The slides  were then  counterstained  with hematoxylin  for 
interpretation by light microscopy. 
 
For each antibody, including negative controls, all TMA stains were performed in one single 
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experiment. HER2 gene status was detectable on one slide, and chromosome 17 probe was 
detectable on a matched slide, which allowed the HER2 gene status to be investigated in the 
context of its chromosomal state using standard light microscopy.  Two discrete black dots 
were observed in the nuclei of cells with normal HER2 gene copy numbers (non-malignant 
cells served as internal positive controls for staining). Small or large clusters of black dots 
were seen in cells with multiple HER2 gene copies, representing HER2 gene-amplified cells. 
More than two discrete black dots were seen in the nuclei of cells with abnormal numbers of 
chromosome 17, indicating polysomy.
Table 3. The investigated antibodies using silver in situ hybridization
Antigen Antibody Catalog # Source Dilution
HER2 (SISH) Anti-rabbit 05273439001 Ventana a
Chromosome 17 (SISH) Anti-rabbit 05273412001 Ventana a
a=Prediluted by the manufacturer
3.5 Scoring
3.5.1 Scoring of immunohistochemistry:
The same scoring system was used in all three papers. By light microscopy, representative 
and  viable  tissue  sections  were  scored  semiquantitatively  for  cytoplasmic  staining.  The 
dominant staining intensity in both tumor cells and stromal cells was scored as: 0 = negative; 
1 = weak; 2 = intermediate; 3 = strong. The cell density of the stroma was scored as: 1 = low 
density;  2  =  intermediate  density;  3  =  high  density.  All  samples  were  anonymized  and 
independently  scored  by  two  pathologists  (S.  Al-Saad  and  K.  Al-Shibli).  In  case  of 
disagreement, the slides were re-examined and a consensus was reached by the observers. In 
most tumor cores as well as in some stromal cores a mixture of stromal cells and tumor cells 
was observed. However, by morphological criteria we have only scored staining intensity of 
tumor cells in tumor cores and intensity of expression and density of tumor related stroma in 
stromal cores. When assessing a variable for a given core, the observers were blinded to the 
scores  of  the  other  variables  and  to  outcome.  In  a  study performed  by our  group,135 the 
interobserver  scoring agreement  was  assessed for one ligand (VEGF-C) and one receptor 
(VEGFR-3). The mean correlation coefficient (r) was 0.95 (range 0.93-0.98). Mean score for 
duplicate  cores from each individual  was calculated separately in tumor cells  and stroma. 
High expression in tumor cells was defined as score ≥ 2 (E-cadherin, p-Akt Thr308, Akt2). For 
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both vimentin and NF-κB p105 an additional moderate expression was defined as >1 and < 3. 




Figure 9. Examples of different grades of IHC expression in tumor cells
Stromal expression was calculated by summarizing density score (1-3) and intensity score (0-
3) prior to categorizing into low and high expression (Figure 10). High expression in stroma 
was defined as score ≥ 2 (NFkB p105, Par6, Akt3 and PI3K). 
Figure 10. Examples of different grades of IHC expression in stromal cells
3.5.2 Scoring of silver in situ hybridization:
There  are  still  no clear  guidelines  established  for  measuring  HER2 gene amplification  in 
NSCLC. In paper  III  we sought  to  determine  whether  the number  of  HER2 gene copies 
detected by SISH (i.e., the number of black dots observed in the nuclei of tumor cells in the 
HER2sish  assay)  would  add  prognostic  significance  beyond  that  established  by  the 
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HER2/chr17 ratio. The number of gene copies was counted according to the manufacturer’s 
protocols for INFORMHER2 DNA. Briefly, a discrete dot was counted as a single copy of 
HER2sish or chromosome 17. Some nuclei showed multiple discrete copies. Clusters of dots 
representing many copies of the HER2 gene were also observed; a small cluster of multiple 
signals was counted as 6 copies and a large cluster was counted as 12 copies (Figure 11). 
According to HER2 gene copies, the mean value was used as cut-off point, defining patients 
having 2.7 gene > copies as patients with high gene copy number.
Figure 11. Examples of different grades of SISH expression in tumor cells
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3.6 Cut-off values 
An ideal  situation  for  the  evaluation  of  different  markers  expression  would  be  defining 
standardized cut-offs points for each specific method. Unfortunately, such standardized cut-
offs are extremely difficult- if not impossible- to imply in daily practice due to variations in 
tissue fixation and preparation, antigen retrieval, and antibody dilution. Additionally,  inter- 
and intraobserver variations can play a major role in defining standardized cut-off values. 
Using the mean value or the median as a cut-off point would appear to be the least statically 
biased decision. However, using the mean value or median as cut-off value will at the same 
time ignore interesting alterations and prognostic expressions of markers in a small group of 
the study population. In our binary and ternary cut-off points of biomarker expressions, the 
cut-offs  were determined for each variable  so that  the resulting subgroups were the most 
dissimilar according to DSS. The main drawback with this approach is the danger of false 
positive  results,  and  especially  borderline  significant  results  in  the analyses  must  be 
interpreted carefully.
3.7 Controls and limitations
Both  reagent  and  tissue  controls  were  used.  Of  all  components  used  for  IHC and  SISH 
analyses, the primary antibody is the most critical. Though, occasionally other reagents may 
need  to  be  replaced.  As  reagent  control,  diluent  without  primary  antibody  was  used  as 
negative control. As tissue controls, both normal lung tissue distant from the primary tumor 
and  lung  tissue  from individuals  without  any  history  of  malignancy  were  used.  Another 
concern to be mentioned is whether variations in tissue storage period over years affected the 
results. The oldest paraffin imbedded tissue blocks used were obtained in 1990. In general, 
archival  blocks dating back 20-40 years  are  considered adequate  for  evaluation,  provided 
initial fixation in 4% buffered formalin.125 While examining the slides, we did not observe 
differences  in  markers  expressions  related  to  variations  of  storage  period.  An  important 
limitation to be mentioned when using immunohistochemistry, is the inability to completely 
exclude  positive  cross-reactions,  i.e.  other  factors  which  would  cause  positive  staining 
reaction using an antibody. Besides, other methods would help investigating the specifity of 
various antibodies. Nevertheless, the specifity of a defined antibody would never exceed the 
specifity of the antibody provided by the manufacturer. 
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3.8 Statistical analysis
Sample size was estimated with survival as the primary endpoint. At least a 50% increase in 
hazard ratio resulting from the presence of a specific  marker  was assumed to represent a 
clinically significant effect. The 5–year DSS for patients with resected NSCLC is about 60%, 
and the frequency of a given level of a specific marker is typically about 35%. Analyzing the 
primary endpoint in a proportional hazards regression with a specific marker at a specific 
level  as  a  dichotomous  independent  variable,  300  subjects  were  considered  necessary  to 
achieve  a  power  of  80% at  an  alpha  of  5% (PASS  2002,  Number  Cruncher  Statistical 
Systems,  Kaysville,  Utah,  USA).  This  estimate  does  not  take  into  account  the  testing  of 
multiple  markers  in  the  actual  analysis,  and  can  only  serve  as  a  rough indication  of  the 
number  of  needed  subjects.  In  all  three  papers,  statistical  analyses  were  done  using  the 
statistical package SPSS (Chicago, IL), version 14 or 15. In a former study,135 the IHC scores 
from each observer were compared for interobserver reliability by use of a two-way random 
effect  model  with  absolute  agreement  definition.  The  intraclass  correlation  coefficient 
(reliability coefficient) was obtained from these results. In all three papers, the Chi-square test 
and  Fishers  Exact  test  were  used  to  examine  the  association  between  molecular  marker 
expression  and  various  clinicopathological  parameters.  Univariate  survival  analyses  were 
done by using the Kaplan-Meier method, and statistical significance between survival curves 
was assessed by the log rank test. Disease-specific survival (DSS) was determined from the 
date of surgery to the time of lung cancer death. To assess the independent value of different 
pretreatment variables on survival, in the presence of other variables, a multivariate analysis 
was  carried  out  using  the  Cox  proportional  hazards  model.  Only  statistically  significant 
variables  from  the  univariate  analysis  were  entered  into  the  Cox  regression  analysis. 
Probability  for  stepwise  entry  and  removal  was  set  at  .05  and  .10,  respectively.  The 
significance level was defined at P < 0.05.
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4. Main results
4.1 Paper I (Markers related to EMT)
The aim of this study was to investigate the prognostic impact of different markers known to 
play an important role in cell differentiation. The expression of the seven markers, vimentin, 
NF-κB p105, fascin, E-cadherin,  TGF-ß, Par6 and atypical PKC, was investigated in both 
tumor cells and stromal cells in 335 primary resected NSCLC tumors. 
All  the  investigated markers except E-cadherin were expressed in the cytoplasm of tumor 
epithelial  cells.  E-cadherin showed a membranous staining.  Expression of the investigated 
markers in tumor epithelial cells or stroma did not correlate with clinical performance status, 
vascular  infiltration  or  histological  subgroups.  Expression  of  vimentin  and Par6 in  tumor 
epithelial  cells  correlated  significantly  (r=0.2,  P=0.001),  as  did  vimentin  and  tumor 
differentiation  (r=-0.1,  P=0.01).  High expression of  vimentin  was seen in  61% of  poorly 
differentiated tumors, 39% of moderately differentiated tumors and no expression was seen in 
well differentiated tumors. Even among the patient group with poorly differentiated tumors, 
high tumor epithelial cell vimentin expression tended to correlate with poor survival (P=0.08). 
Further, a significant correlation was seen between tumor epithelial expression of aPKC and 
Par6 (r=0.2, P=0.001).
In univariate analyses, high tumor epithelial cell expressions of NF-κB  p105 (P=0.02) and E-
cadherin  (P=0.03) were positive  prognostic  indicators  for  disease-specific  survival  (DSS), 
whereas  high  tumor  epithelial  cell  expression  of  vimentin  (P=0.001)  was  a  negative 
prognostic indicator. In the stromal compartment, high expression of NF-κB p105 (P=0.001) 
and Par6 (P=0.0001) correlated with a good prognosis.
In multivariate analyses, low tumor epithelial cell expression of NF-κB  p105 (HR 7.1, CI 
95%  2.18-23.2,  P=0.0001)  and  high  vimentin  expression  (HR  2.70,  CI  95%  1.44-5.04, 
P=0.005)  were unfavorable  independent  prognostic  factors.  Furthermore,  low stromal  cell 
expression of NF-κB p105 (HR 2.16, CI 95% 1.23-3.80,  P=0.007) and low Par6 expression 
(HR 2.46, CI 95% 1.66-3.64, P=0.0001) were unfavorable independent prognostic factors for 
DSS.
37
4.2 Paper II (PI3K/Akt pathway)
In this study we investigated the prevalence and prognostic significance of the expression of 
altered Akt isoforms, PTEN and PI3K in primary resected NSCLC tissue. When compared to 
20 lung tissue cores from patients without any history of malignancy PTEN expression was 
significantly higher in control tissue when compared to tumor tissue (P=0.001). There was a 
significantly  negative  correlation  between PI3K expression  in  control  versus  tumor  tissue 
(P=0.001, r=–0.2).
All  the investigated Akt markers  were expressed in the cytoplasm of the tumor epithelial 
cells. A weak positive nuclear staining was observed in some cores. Nuclear staining was seen 
to be related to cytoplasmic staining, with more pronounced nuclear staining in cores with 
high cytoplasmic expression. Expression of the investigated markers in tumor epithelial cells 
and stroma did not correlate with age, gender, smoking, clinical performance status, vascular 
infiltration, tumor differentiation or histological type.
In  univariate  analyses,  high  tumor  epithelial  cell  expression  of  non-phosphorylated  Akt2 
(P=0.014) was a positive prognostic indicator for disease-specific survival (DSS), while high 
tumor  epithelial  cell  expression  of  p-Akt  Thr308 (P=0.045)  was a  negative  prognosticator. 
High stromal expression of total Akt3 (P=0.0008) and total PI3K (P=0.0003) correlated with 
a good prognosis. 
Prognostic relevance of the concomitant phosphorylation of both sites of activated Aktl (p-
Akt  Ser473and  p-Akt  Thr308)  was  evaluated.  Ninty-eight  percent  of  the  tumors  were 
phosphorylated  at  both  sites.  There  was  no  significant  association  between  DSS and  the 
concomitant expression of phosphorylated Akt (Ser473 and Thr308) in tumor epithelial (P=0.2) 
or stromal cells (P =0.09).
In the multivariate analysis, high tumor epithelial cell expression of p-Akt Thr308 (HR 1.98, CI 
95% 1.36-2.88,  P=0.0009) and low tumor epithelial cell expression of Akt2 (HR 2.91, CI 
95% 1.39-6.08, P=0.004) were unfavorable independent prognostic factors. Furthermore, low 
stromal cell expression of Akt3 (HR 3.82, CI 95% 1.96-7.45, P=0.0008) and PI3K (HR 1.84, 
CI 95% 1.15-2.96, P=0.012) were unfavorable independent prognostic factors for DSS.
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4.3 Paper III (Erb family members)
Herein,  we  compared  the  efficacy  of  silver  in  situ hybridization  (SISH)  and 
immunohistochemistry  (IHC)  in  detection  of  HER2  alterations  and  investigated  the 
prevalence and prognostic significance of Erb family members in NSCLC. 
We found overexpression of EGFR, HER2, HER3, HER3n (nuclear), HER4 and HER2sish in 
41%,  38%,  34%,  38%,  39%  and  38%  of  tumor  samples,  respectively.  Polysomy  of 
chromosome 17 was seen in 14% of valid cases.  Synchronous high expression of all  Erb 
family  members  was  seen  in  5%  of  tumor  samples,  while  19%  of  samples  showed 
synchronous low expression. 
Epidermal growth factor receptors did not correlate with gender, histological subtypes, WHO 
performance  status  or  vascular  infiltration.  Overexpression  of  EGFR correlated  positively 
with  the  expression  of  HER3 (P=0.0001),  HER3n (P=0.0001)  and  HER4 (P=0.0001).  A 
significantly higher expression of EGFR was noted in patients who were smokers or former 
smokers  (P=0.028)  when  compared  to  non-smokers.  Membranous  HER2  overexpression 
correlated significantly with higher HER2 gene copy number (P=0.003). Overexpression of 
HER3n correlated significantly with the expression of cytoplasmic HER3 (P=0.0001) and 
HER4 (P=0.0001) and with higher HER2 copy numbers (P=0.015). Additionally,  a higher 
nuclear HER3 expression was seen in patients with polysomy of chromosome 17 (P=0.003).
HER4 expression correlated positively with tumor status (T-stage,  P=0.028). A high HER2 
gene copy number correlated positively with nodal status (P=0.046). In 73% (77/105) of all 
patients with a high HER2 gene copy number, simultaneous polysomy of chromosome 17 was 
observed. There was a significantly negative correlation between polysomy of chromosome 
17  and  tumor  differentiation  (P=0.023).  There  was  a  significant  correlation  between  the 
HER2 gene copy number and HER2 protein expression (P=0.003). 
In  univariate  analyses,  high  HER2 gene  copy  number  was  a  highly  significant  negative 
prognostic indicator for disease-specific survival (DSS) in female patients (P=0.005), while it 
did not show prognostic influence in men (P=0.9). Neither polysomy of chromosome 17 nor 
the IHC expression of Erb family member proteins as singles or pairs correlated significantly 
with survival. In the multivariate analysis, high HER2 gene copy number in tumor epithelial 
cells (HR 2.50, CI 95% 1.09-5.75, P=0.03) was an unfavorable independent prognostic factor 
for DSS in female patients.
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5. Discussion
5.1 Discussion of results
Our study population is relatively large compared with other studies investigating NSCLC. 
Expressions  of  the  investigated  biological  markers  were  performed  by  two  pathologists 
adding  more  objectivity  to  the  scoring  procedure.  An  experienced  oncologist  collected 
comprehensive clinical data for each individual with a relatively long follow up (median 86 
months, minimum 48 months) allowing sufficient statistic for correlative and also multivariate 
analyses.  All patients had primary resected NSCLC without any other known malignancy. 
The  histological  diagnosis  and  pathological  stage  was  revised  by  the  two  experienced 
pathologists for all patients. Due to the large number of commercial antibodies available for 
immunohistochemistry,  we had the possibility to investigate the prevalence and prognostic 
impact not only of biological markers related to cell proliferation and differentiation, but also 
to investigate additional highly interesting markers related to angiogenesis135-137 and  in-situ 
immunity.138,  139 Using an additional method, SISH, we were able to investigate the HER2 
gene status and to correlate it to its encoded protein expression. On the other hand, a general 
concern using commercial antibodies would be the specifity of the antibodies provided by the 
manufacturer.  However,  local  experiences  at  UNN  and  NLSH  with  different  antibody 
providers were taken critically into consideration, while selecting our antibody providers.
5.1.1 Paper I
In this study we identified a positive independent prognostic impact by highly expressed NF-
κB  p105  both  in  epithelial  cells  and  in  stromal  cells.  Being  activated  in  a  range  of 
inflammatory processes and human cancers, the transcription factor NF-κB is thought to play 
an important role in tumorigenesis. The functional link between inflammation and cancer is 
not  new.  As  early  as  1863,  Virchow  hypothesized  a  correlation  between  inflammatory 
processes  and  the  development  of  tumors.52 Among  the  best  documented  are  the  causal 
relationship between Helicobacter pylori and mucosa-associated lymphoid tissue lymphoma 
of the stomach, and between the helminth worm Schistosoma hematobium and bladder cancer. 
Furthermore,  risk  factors  such  as  asbestos  and  tobacco  inhalation  cause  a  chronic 
inflammation  state  that  can  promote  tumorigenesis.53 NF-κB  p105  is  the  cytoplasmic 
precursor protein for NF-κB 1 (p50). High cytoplasmic expression of NF-κB -as observed in 
our  study-  have  been  interpreted  as  a  higher  amount  of  inactivated  cytoplasmic  NF-κB 
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protein, since degradation of the IkB protein results in the liberation of NF-κB, allowing its 
nuclear  translocation  and  the  activation  of  target  genes  (Figure  5).  The  same  positive 
prognostic impact for the precursor protein NF-κB was also observed in stromal cells. This 
correlation between NF-κB inactivation in stromal cells and better prognosis gives a special 
emphasis on the role of stromal cells in oncogenesis. There is mounting evidence, proposing 
the  formation  of  tumor-specific  stromal  cells  with  paradoxical  influence  on  tumor 
progression.  In  fact,  Giatromanolaki  and  co-workers  described  a  process  termed 
“stromatogenesis”  indicating  a role  for tumor-specific  stromal  cells  promoting  cancer  cell 
progression and invasion.140
These observations both in tumor epithelial and stromal cells  underscore the importance of 
considering the regulating of NF-κB activity as part of future anticancer therapy.  Already, 
there are dithiocarbamate compounds which can inhibit the NF-κB cascade, but preclinical 
laboratory investigations are still ongoing to succeed making such substances applicable as 
cancer drug therapies.141
The finding that high tumor epithelial cell expression of vimentin is associated with a worse 
prognosis seems at first to be of minor interest taking into account the large number of papers 
reporting a similar association.142-148 However, we decided to investigate the prognostic impact 
of  vimentin  in  NSCLC not  only  because  it  is  considered  one  of  the  most  known tumor 
differentiation markers, but also because such a finding will give us more confidence in our 
method  of  staining  and  scoring  and  can  be  regarded  as  a  control  marker  for  our  study 
construction. 
We found high Par6 stromal cell expression to be an independent favorable prognostic factor, 
indicating  an  anti-tumor  effect  of  motile  and proliferative  stromal  cells.  This  effect  is  in 
concert with the assumed function of the immune system. Such observations with apparently 
different impact on tumorigenesis of the same marker in different tumor compartments will 
open new and unique horizons for investigating tumor biology and progression and seem to 
be critical in considering new targets for cancer therapies.
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5.1.2 Paper II
In tumor epithelial cells, we observed high expression of p-Akt Thr308 to be an independent 
negative prognostic factor  for DSS and high non-phosphorylated Akt2 expression to be a 
positive prognosticator. In stromal cells, high expression of total Akt3 and PI3K were both 
independent positive prognostic factors for DSS. 
While several studies confirmed a negative prognostic role for phosphorylated Akt and its 
isoforms,110, 149-151 only few studies151 investigated its prognostic impact when phosphorylated 
at both its activation sites; the serine 473 and the threonine 308. Our investigations did not 
confirm an additional prognostic role for Akt, when phosphorylated at its serine 473 amino 
acid, as proposed by Tsurutani et al.,151 but we were the first to report an independent positive 
prognostic role for the non-phosphorylated Akt2 isoform in NSCLC. Whether the observed 
overexpression  of  non-phosphorylated  Akt2  indicates  a  lower  presence  of  phosphorylated 
(active) Akt2 or whether these findings represent opposing prognostic roles of phosphorylated 
(active)  and non-phosphorylated  Akt  isoforms  deserves  further  investigation.  An apparent 
limitation for such an investigation is the problem finding a sufficiently specific antibody for 
phosphorylated Akt2 on paraffin-embedded material.  While  performing our investigations, 
we were unable to find a commercially available antibody with reliable specificity. Additional 
studies will be of interest as soon as more specific antibodies are available. Identifying high 
stromal Akt3 and PI3K expressions as independent positive prognostic factors, demonstrates a 
complicated epithelial-stromal cell interaction, which deserves further attention. It is likely to 
assume that expression of a molecular marker or its isoforms can have opposing prognostic 
effects  in  different  tumor  compartments.  Such  an  observation  would  encourage  further 
investigations  regarding  the  specifity  of  potential  cancer  drug  therapies  inhibiting  the 
PI3K/Akt signaling pathway, and whether a specific targeting of only epithelial or stromal 
cells to inhibit the Akt cascade is possible.
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5.1.3 Paper III
In this paper we  report about a significant correlation between HER2 gene copy numbers 
assessed by means of silver in situ hybridization and gender specific survival in NSCLC.
While various studies23, 27,  29 indicated EGFR as a possible prognostic or predictive target in 
NSCLC,  other  studies  including  our  could  not  immunohistochemically  confirm  such  an 
association. In stead we investigated the gene and were able to identify high HER2 gene copy 
number  as  a  highly  specific  and  independent  negative  prognosticator  in  female  NSCLC 
patients, while its alteration in males did not have influence on prognosis. Our observations 
deserve further attention if taking into account specific mutations in the tyrosine kinase region 
of the EGFR gene, which were more frequently observed also in females in addition to lung 
adenocarcinomas,  non-smokers and Asians.28,  29 In a recent study using mRNA expression 
values,  Vallbohmer  et  al,152 found  HER2  to  be  a  substantial  gender  specific  negative 
prognostic  factor  for  females,  but  not  for  males.  These  gender  differences  in  cancer 
tumorigenesis  and  prognosis  are  most  likely  related  to  different  sex  hormone  effects  on 
various genes, and seem to be of huge interest for planning anti-cancer drug therapy regimes. 
The recent identifying of specific alterations of HER2 protein and gene expression in breast 
cancer has dramatically improved survival in about 30% of female breast cancer patients,153-155 
after introducing the anti-HER2 drug trastuzumab. In our study, about 38% of female patients 
showed a high HER2 gene copy number. These findings deserve further future translational 
prospective studies to confirm the role of HER2 as a prognostic and possibly as a predictive 
marker for female NSCLC patients. 
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6. Conclusions and implications for future research
Our research group has, in NSCLC patients, studied the prevalence and prognostic impact of 
multiple markers expected to influence tumor proliferation and differentiation. 
Using the TMA technology gave us the possibility to study a large-scale of biological markers 
regarding tumor differentiation markers, angiogenic markers and markers related to the innate 
immune system. Several markers were found to be independent prognostic factors in NSCLC. 
We learned, however, a new aspect of epithelial-stromal cell interactions and were able to 
recognize  -in  some  instances-  opposing  roles  of  protein  isoforms  in  different  tumoral 
compartments. Employing new methodology, such as SISH gave us the possibility to reveal 
an interesting correlation between gene status and survival in female NSCLC patients. 
Our group has the aim to continue the translational work bridging basic and clinical research 
to identify new important markers in NSCLC. We are presently introducing new research 
strategies such as micro RNA expression to enhance the knowledge and understanding of 
tumor biology. Additionally,  we are establishing short-term cell-lines from freshly resected 
NSCLC tumor tissue, which will give us additional possibilities to understand the somehow 
shadowy, but very challenging process of tumor progression. Enhancing our knowledge in 
this  field is a prerequisite to develop new and more specific strategies to reduce the fatal 
outcomes of this aggressive malignancy.
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